AZD6912 / AstraZeneca - LARVOL DELTA

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed | Trial completion date: Mar 2026 ➔ Oct 2025 | Trial primary completion date: Mar 2026 ➔ Oct 2025

Trial completion • Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting | N=64 ➔ 40 | Trial completion date: Sep 2026 ➔ Mar 2026 | Trial primary completion date: Sep 2026 ➔ Mar 2026

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Dec 2025 ➔ Aug 2026 | Trial primary completion date: Dec 2025 ➔ Aug 2026

Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Targeting Complement Factor B (CFB) via a Novel siRNA Therapy (AZD6912) to Treat Inflammatory Arthritis (ACR Convergence 2024) - "Suppression of CFB using a GalNAC targeting siRNA demonstrated that inhibition of hepatic CFB was sufficient to reduce articular inflammation and damage in the murine CAIA model. In non-human primates AZD6912 suppressed CFB levels and complement alternative pathway activity. Dose-to-man modelling predictions and toxicology studies in cynomolgus monkeys support progression into the clinic."

Dermatology • Immunology • Inflammation • Inflammatory Arthritis • Rheumatology • CFB • ITGAM

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Jul 2025 ➔ Nov 2025 | Trial primary completion date: Jul 2025 ➔ Nov 2025

Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

TARGETING COMPLEMENT FACTOR B (CFB) VIA A NOVEL SIRNA THERAPY (AZD6912) TO TREAT INFLAMMATORY ARTHRITIS (EULAR 2024) - "Suppression of CFB using a GalNAC targeting siRNA demonstrated that inhibition of hepatic CFB was sufficient to reduce articular inflammation and damage in the murine CAIA model. In non-human primates AZD6912 suppressed CFB levels and complement alternative pathway activity. Dose-to-man modelling predictions and toxicology studies in cynomolgus monkeys support progression into the clinic."

Dermatology • Immunology • Inflammatory Arthritis • Rheumatology • CFB • ITGAM

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Feb 2025 ➔ Jun 2025 | Trial primary completion date: Feb 2025 ➔ Jun 2025

Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology